First quarter results to be discussed at the company’s annual and special meeting of shareholders which will be Webcast live with question and answer session
TORONTO, Feb. 21 /PRNewswire-FirstCall/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will report its first quarter fiscal 2011 financial results on Thursday, March 10, 2011.
In conjunction with the company’s earnings announcement, the company will be holding its Fiscal 2010 annual and special meeting of shareholders. Patheon representatives will provide a brief overview of Fiscal 2010 results and Fiscal 2011 first quarter results as part of the meeting and will take questions from those investors in attendance and, via the Webcast, from analysts and institutional investors who are not able to attend the meeting. Presentation slides will be posted to Patheon’s Web site prior to the meeting which will begin at 10:00 a.m. (EST). The Fiscal 2011 first quarter financial results news release will be issued at approximately 8:00 a.m. (EST) on Thursday, March 10, 2011.
Interested parties are invited to access the live meeting and conference call, via telephone, in listen-only mode, toll free at 1-888-231-8191 (U.S., including Puerto Rico) and 1-647-427-7450 (Canada and International). Listeners are encouraged to dial in five to fifteen minutes in advance to avoid delays. A live audio will also be available via the web at http://www.patheon.com. (Please note that Windows Media Player or RealPlayer is required).
A telephone replay of the conference call will be available between Thursday, March 10, 2011 and Thursday, March 17, 2011 by dialling 1-800-642-1687(toll free) or 1-403-451-9481, and by entering identification number 45029866, followed by the number key. The conference call will also be archived at http://www.patheon.com.
ABOUT PATHEON
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world’s leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies.
The company’s comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon’s Quick to Clinic programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. The company’s integrated development and manufacturing network of 11 facilities, and eight development centers across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.
